Ivermectine (oraal)

Generic name
Ivermectine (oraal)
Brand name
ATC Code
P02CF01
Compare …

Ivermectine (oraal)

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

Brussee et al. 2019 found the following pharmacokinetic parameters (median (90% confidence interval)) after a single oral administration:

Age n= dose CL (L/hour/kg)
2-5 years 80 0,1 of 0,2 mg/kg 0,346 (0,12-0,73)
6-12 years 120 0,2-0,6 mg/kg 0,352 (0,17-0,69)

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Strongyloidiasis, scabies, myiasis caused by Hypoderma tarandi
Microfilaremia
  • Oral
    • 1 month up to 18 years
      [1] [2] [4] [5] [7] [8]
      • 0.15 - 0.2 mg/kg/dose once every 6 months. Double the dose if yearly administration is the only feasible option..

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Slightly elevated creatine kinase concentrations (Stander 2020).

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions

No information available on specific warnings and precautions in children.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

ANTINEMATODAL AGENTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Benzimidazole derivatives
P02CA03
P02CA01
Tetrahydropyrimidine derivatives
P02CC01
Imidazothiazole derivatives
P02CE01

References

  1. Merck Sharp & Dohme BV, SmPC Stromectol (RVG 28341) 03-09-2015, www.geneesmiddeleninformatiebank.nl
  2. Gwee, A., et al. , Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children, PLoS Negl Trop Dis, 2020, 14 (12), e0008886
  3. Nordal, E., et al. , Acute Seizures in a 10-Year Old Boy., Pediatr Infect Dis J, 2020, 39 (11), 1063-1064
  4. Levy, M., et al. , Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study., Br J Dermatol, 2020, 182 (4):1, 003-1006
  5. Bécourt, C., et al. , Treatment of scabies with oral ivermectin in 15 infants: a retrospective study on tolerance and efficacy, Br J Dermatol, 2013, 169 (4), 931-3
  6. Brussee, J. M., et al. , Ivermectin Dosing Strategy to Achieve Equivalent Exposure Coverage in Children and Adults, Clin Pharmacol Ther, 2019, 106 (3), 661-667
  7. Ständer, S., et al., Effectiveness and adverse events of ivermectin treatment for scabies in 30 infant patients: report from a German single centre, J Eur Acad Dermatol Venereol, 2020, 34 (11, e736-e737
  8. Wilkins, A. L., et al. , Question 1: Is it safe to use ivermectin in children less than five years of age and weighing less than 15 kg?, Arch Dis Child, 2018, 103 (5), 514-519
  9. Kan, B., et al. , Reindeer warble fly-associated human myiasis,Scandinavia, Emerg Infect Dis, 2013, 19 (5), 830-2

Changes

Therapeutic Drug Monitoring


Overdose